Shilpa Sambashivan

from Los Altos, CA

Age ~44

Get Report

Shilpa Sambashivan Phones & Addresses

1439 Aura Way, Los Altos, CA 94024
Menlo Park, CA
San Mateo, CA
Sunnyvale, CA
Los Angeles, CA

Work

Company: Amgen inc. Mar 2013 Address: South San Francisco Position: Sr. scientist

Education

Degree: Ph.D. School / High School: University of California, Los Angeles 2001 to 2006 Specialities: Molecular Biology and Protein Biochemistry

Skills

Assay Development • Molecular Biology • Biochemistry • Drug Discovery • Life Sciences • Biotechnology • Protein Chemistry • Cell Culture • Cell Biology

Languages

English

Industries

Biotechnology

Resumes

Vice President, Biology

View page

Location:

1439 Aura Way, Los Altos, CA 94024

Industry:

Biotechnology

Work:

Amgen Inc. - South San Francisco since Mar 2013
Sr. Scientist
Amgen May 2011 - Feb 2013
Scientist
NGM Biopharmaceuticals Inc. Jun 2009 - May 2011
Scientist
Stanford University Jan 2007 - May 2009
Genentech Foundation Postdoctoral Fellow
Stanford University 2007 - 2009
Postdoctoral Fellow

Education:

University of California, Los Angeles 2001 - 2006
Ph.D., Molecular Biology and Protein Biochemistry Birla Institute of Technology and Science 1997 - 2001
MSc. (Hons), Biological Sciences National Public School

Skills:

Assay Development
Molecular Biology
Biochemistry
Drug Discovery
Life Sciences
Biotechnology
Protein Chemistry
Cell Culture
Cell Biology

Languages:

English

Publications

Us Patents

Trem2 Antigen Binding Proteins And Uses Thereof

View page

US Patent:

20210054069, Feb 25, 2021

Filed:

Apr 20, 2018

Appl. No.:

16/500378

Inventors:

- Thousand Oaks CA, US
Shilpa Sambashivan - Menlo Park CA, US
Irwin Chen - Los Angeles CA, US
Susie Miki Harris - Newbury Park CA, US
Dora Toledo Warshaviak - Oak Park CA, US
Ian Driver - San Francisco CA, US
Daniel Lu - San Jose CA, US

Assignee:

AMGEN INC. - Thousand Oaks CA

International Classification:

C07K 16/28
A61P 25/28

Abstract:

The present invention relates to antigen binding proteins, such as monoclonal antibodies, that specifically bind to and activate human triggering receptor expressed on myeloid cells-2 (TREM2) and pharmaceutical compositions comprising such antigen binding proteins. The agonist antigen binding proteins (e.g. antibodies) of the invention are capable of activating TREM2/DAP12 signaling in myeloid cells in the absence of Fc-mediated cross-linking of the antigen binding proteins. Methods of treating or preventing conditions associated with TREM2 loss of function, such as Alzheimer's disease and multiple sclerosis, using the antigen binding proteins are also described.